Transfusion of Cold-stored Platelet Concentrates (4CPLT)

May 31, 2021 updated by: Haukeland University Hospital

Transfusion Therapy in Patients Undergoing Cardiac Surgery in Combination With Late Withdrawal of Drug Induced Platelet Inhibition or Prolonged Extra-corporal Circulation Time

This study will investigate the effects of Leukocyte reduced cold-stored platelet transfusions used in treatment of immediate postoperative blood loss in patients undergoing thoracic surgery in combination with extracorporal circulation. Today platelet concentrates are stored at 22 degrees C .

This is a prospective, randomized, unblinded, non-inferiority two-arm study. Aim of study is to compare platelet function in bleeding patients transfused with leukoreduced platelet concentrates stored cold (4 degrees C) and in room temperature (22 degrees C). Storage time for RCT platelet concentrates are up to 7 days. Patients with expected time on extracorporal circulation more than 120 minutes and/or medical platelet inhibitors will be included.

Platelet function will be assessed by use of Multiplate Aggregometry, Thromboelastography (TEG) and/or Thromboelastometry (ROTEM). In addition post operative bleeding, and adverse events will be recorded.

After completion of recruitment of patients to RCT study of platelet stored cold for up to 7 days, a follow up prospective observational study of platelets stored cold for up to 14 days is performed.

Additonal information 2019, May 03: This trial was registered on Clinical Trials.gov with an original plan to use non-inferiority testing of between-group differences in platelet function. Due to lack of evidence needed to set acceptable tolerance margins for the non-inferiority testing, independent reviewers with expertise in clinical trial design recommended they be replaced by standard tests of superiority, commensurate with the early phase of the trial. Further, post-operative chest tube drainage was chosen as the primary outcome to better present the pilot study's focus on the control of clinically significant bleeding.

Study Overview

Detailed Description

This is a prospective, randomized, unblinded, non-inferiority two-arm study were Arm 1 patients will receive Leukocyte reduced cold-stored platelet concentrates and Arm 2 patients will receive leukoreduced room-temperature-stored (22 degrees C) platelet concentrates. Patients with expected time on extracorporal circulation more than 120 minutes and/or medical platelet inhibitors will be included.

The number of patients included is set to 20 patients in each arm, as there is not sufficient information available in the literature to conduct power calculations. The hypothesis is that cold stored platelets are not inferior to room temperature platelet concentrates.

Baseline patient data and information on intervention and post operative recovery will be collected from the Medical journals together with information on transfusion episodes and Blood Components. Blood samples will be retrieved from study participants at specific intervals: baseline, immediately after surgery, at arrival at ICU, before and after (every) platelet transfusion episode, 24 hours post operation, and if indicated, during hospital stay. Blood samples will be investigated for platelet function, coagulation parameters, hematologic parameters, and other risk factors for adverse events. If transfusion reactions occur, additional test of patient and the Blood Component(s) transfused will be performed. Samples will be collected and stored in the biobank for cytokines, complement and allergy analysis.

After completion of recruitment of patients to RCT study of platelet concentrates stored cold for up to 7 days, a follow up prospective observational study of platelets stored cold for up to 14 days is performed.

Additonal information 2019, May 03: This trial was registered on Clinical Trials.gov with an original plan to use non-inferiority testing of between-group differences in platelet function. Due to lack of evidence needed to set acceptable tolerance margins for the non-inferiority testing, independent reviewers with expertise in clinical trial design recommended they be replaced by standard tests of superiority, commensurate with the early phase of the trial. Further, post-operative chest tube drainage was chosen as the primary outcome to better present the pilot study's focus on the control of clinically significant bleeding.

Study Type

Interventional

Enrollment (Actual)

65

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bergen, Norway
        • Haukeland University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients undergoing urgent/semiurgent thoracic surgery
  • Expected long extracorporal time (>120 minutes) and/or use of dual platelet inhibition drugs
  • Patients likely to require platelet transfusion
  • Patients capable of providing informed consent

Exclusion Criteria:

  • Patients who will not provide informed consent
  • Patients with congenital coagulopathies or hemostatic disorders (von willebrands disease, hemophilia etc)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cold stored platelets
Intervention: Leukoreduced platelet concentrates stored at 4 degrees C for treatment of bleeding after Cardiac surgery
Intervention: Leukoreduced platelet concentrates stored at 4 degrees C for treatment of bleeding after Cardiac surgery. Storage time for RCT platelet concentrates are up to 7 days.
Other Names:
  • Trombocytes, Platelet concentrates
Active Comparator: Room temperature platelets
Intervention: Leukoreduced platelet concentrates stored at 22 degrees C for treatment of bleeding after Cardiac surgery
Intervention: Leukoreduced platelet concentrates stored at 22 degrees C for treatment of bleeding after Cardiac surgery. Storage time for RCT platelet concentrates are up to 7 days.
Other Names:
  • Trombocytes, Platelet concentrates

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Chest drain output (postoperative bleeding)
Time Frame: 24 hours
Information retrieved from Medical Journal
24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evidence of altered platelet function confirmed by Point-of-Care measurements
Time Frame: Up to 24 hours after surgery
Evaluate in vitro changes in platelet function by use of the following Point-of-Care measurements; Multiplate whole blood impedance aggregometry, Thromboelastography, and ROTEM
Up to 24 hours after surgery
Number of Blood Products transfused as a Measure of Bleeding
Time Frame: From date of inclusion during hospital stay, up to 4 weeks
Information retrieved from Medical Journal
From date of inclusion during hospital stay, up to 4 weeks
Number of Participants with thromboembolic events as a Measure of Safety
Time Frame: From date of procedure until the date of first documented event during hospital stay, up to 4 weeks
Information retrieved from Medical Journal
From date of procedure until the date of first documented event during hospital stay, up to 4 weeks
Number of Participants with other adverse events as a Measure of Safety
Time Frame: From date of procedure until the date of first documented event during hospital stay, up to 4 weeks
Information retrieved from Medical Journal
From date of procedure until the date of first documented event during hospital stay, up to 4 weeks
Number of Participants with transfusion complication as a Measure of Safety
Time Frame: From date of procedure until the date of first documented event during hospital stay, up to 4 weeks
Information retrieved from Medical Journal
From date of procedure until the date of first documented event during hospital stay, up to 4 weeks
Hemoglobin value
Time Frame: From date of inclusion, daily during hospital stay, up to 4 weeks
Information retrieved from Medical Journal
From date of inclusion, daily during hospital stay, up to 4 weeks
Hematocrit
Time Frame: Up to 24 hours after surgery
Information retrieved from Medical Journal
Up to 24 hours after surgery
Leukocyte count
Time Frame: Up to 24 hours after surgery
Information retrieved from Medical Journal
Up to 24 hours after surgery
Platelet count
Time Frame: From date of inclusion, daily during hospital stay, up to 4 weeks
Information retrieved from Medical Journal
From date of inclusion, daily during hospital stay, up to 4 weeks
Fibrinogen
Time Frame: Up to 24 hours after surgery
Information retrieved from Medical Journal
Up to 24 hours after surgery
International normalized ratio (INR)
Time Frame: Up to 24 hours after surgery
Information retrieved from Medical Journal
Up to 24 hours after surgery
Activated Partial Thromboplastin time (APTT)
Time Frame: Baseline, up to 24 hours and at the date of first documented thromboembolic event during hospital stay, up to 4 weeks
Information retrieved from Medical Journal
Baseline, up to 24 hours and at the date of first documented thromboembolic event during hospital stay, up to 4 weeks
Allergy analysis as a Measure of Risk of transfusion complication
Time Frame: Baseline,and the date of first documented event during hospital stay, up to 4 weeks
Information retrieved from Medical Journal
Baseline,and the date of first documented event during hospital stay, up to 4 weeks
Complement analysis as a Measure of risk of transfusion complication
Time Frame: Baseline,and the date of first documented event during hospital stay, up to 4 weeks
Information retrieved from Medical Journal
Baseline,and the date of first documented event during hospital stay, up to 4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Geir Strandenes, MD, Haukeland University Hospital
  • Study Director: Torunn Apelseth, MD/PhD, Haukeland University Hospital
  • Study Chair: Einar Kristoffersen, MD/PhD, Haukeland University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2015

Primary Completion (Actual)

December 1, 2020

Study Completion (Actual)

December 1, 2020

Study Registration Dates

First Submitted

June 19, 2015

First Submitted That Met QC Criteria

July 8, 2015

First Posted (Estimate)

July 13, 2015

Study Record Updates

Last Update Posted (Actual)

June 2, 2021

Last Update Submitted That Met QC Criteria

May 31, 2021

Last Verified

September 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • 2014/692

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bleeding

Clinical Trials on Cold stored platelets

3
Subscribe